What is the optimal management of severe pain in Crohn's disease?

Management of Severe Pain in Crohn's Disease

For severe pain in Crohn's disease, prioritize treating the underlying inflammatory disease activity with advanced therapies (TNF antagonists, IL-23 inhibitors, or JAK inhibitors) rather than relying on analgesics, as pain control improves when disease remission is achieved. 1, 2

Understanding Pain in Crohn's Disease

Severe Crohn's disease is characterized by daily abdominal pain alongside other features including:

• At least 10 loose stools per day 1
• Large or deep mucosal lesions on endoscopy 1
• Presence of fistulas, perianal abscesses, or strictures 1
• Elevated inflammatory markers (C-reactive protein) and low albumin 1
• Significant impact on activities of daily living 1

Critically, 20-50% of patients in clinical remission still experience abdominal pain, indicating pain can be multifactorial beyond active inflammation alone. 3

Primary Strategy: Treat the Underlying Disease

First-Line Advanced Therapies for Biologic-Naïve Patients

The AGA strongly recommends using advanced therapies over no treatment for moderate-to-severe disease. 2 The highest efficacy options include:

• Infliximab (moderate-to-high certainty evidence) 4, 2
• Adalimumab (moderate-to-high certainty evidence) 4, 2
• Risankizumab (IL-23 inhibitor, moderate-to-high certainty evidence) 4, 2
• Guselkumab (IL-23 inhibitor, moderate-to-high certainty evidence) 4, 2
• Ustekinumab (IL-12/23 inhibitor, moderate-to-high certainty evidence) 4, 2

The AGA suggests using these higher efficacy medications rather than lower efficacy options like certolizumab pegol or upadacitinib in treatment-naïve patients. 2

For Biologic-Exposed Patients with Persistent Severe Pain

If patients have failed prior biologics, the evidence supports:

• Risankizumab or guselkumab (highest efficacy, moderate certainty evidence) 4, 2
• Adalimumab or upadacitinib (high efficacy, moderate-to-high certainty evidence) 4, 2
• Ustekinumab or mirikizumab (intermediate efficacy) over vedolizumab (lower efficacy) 4, 2

IL-23 antibodies appear particularly effective following loss of response to TNF antibodies. 5

Analgesic Use: What the Evidence Shows

Current Real-World Practice

Pain medication use remains extremely common even after initiating advanced therapies: 6

• 78% of CD patients receive glucocorticoids before advanced therapy initiation 6
• 49% receive opioids 6
• 29% receive neuromodulators 6
• 23% receive NSAIDs 6

Changes After Advanced Therapy Initiation

After 12 months of advanced therapy, pain medication use decreases but remains substantial: 6

• Glucocorticoid use drops from 78% to 59% (p<0.001) 6
• Opioid use drops from 49% to 42% (p=0.004) 6
• NSAID use drops from 23% to 15% (p<0.001) 6
• Neuromodulator use actually increases from 29% to 34% (p=0.007) 6

Specific Pain Management Interventions: Limited Evidence

A Cochrane systematic review found very low certainty evidence for most pain-specific interventions in Crohn's disease. 3 The only intervention with even low certainty evidence was:

• Transcranial direct current stimulation may improve pain intensity compared to sham (MD -1.65,95% CI -3.29 to -0.01, low certainty) 3

All other interventions had very uncertain effects: 3

• Low FODMAP diet (very low certainty) 3
• Mindfulness with CBT (very low certainty) 3
• Stress management (very low certainty) 3
• Olorinab (cannabinoid receptor agonist, very low certainty) 3
• Yoga, relaxation training, osteopathic treatment (all very low certainty) 3

Critical Pitfalls to Avoid

Do not use NSAIDs routinely for pain control - they can exacerbate intestinal inflammation and their use decreases after effective advanced therapy 6. While 15-23% of patients still use them, this represents suboptimal management 6.

Avoid chronic opioid use - nearly half of patients receive opioids, but this does not address underlying inflammation and carries significant risks 6. The persistence of opioid use (42% at 12 months) despite advanced therapy suggests inadequate disease control 6.

Do not rely on corticosteroids for long-term pain management - while 78% of patients receive steroids initially, they are only suitable for short-term control of acute flares 5. Continued steroid use beyond induction indicates treatment failure 1, 5.

Thiopurine monotherapy should not be used for induction - the AGA suggests against this approach due to inferior efficacy compared to biologics 2, 5.

Practical Algorithm

1. Assess disease activity comprehensively - measure inflammatory markers (CRP), perform endoscopy to evaluate mucosal lesions, and assess for complications (strictures, fistulas, abscesses) 1

2. If biologic-naïve with severe pain: Initiate infliximab, adalimumab, risankizumab, guselkumab, or ustekinumab 2

3. If biologic-exposed with severe pain: Switch to risankizumab, guselkumab, or upadacitinib as highest efficacy options 4, 2

4. For immediate symptom relief during induction: Short-term corticosteroids are acceptable, but plan discontinuation within weeks 5

5. If pain persists despite remission: Consider neuromodulators (their use increases appropriately after advanced therapy initiation) 6, or evaluate for non-inflammatory causes (strictures requiring dilation/surgery, visceral hypersensitivity, functional overlay) 3

6. Avoid chronic NSAID or opioid use - their continued use suggests inadequate disease control requiring therapy optimization 6